Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing

An update from Milestone Pharmaceuticals ( (MIST) ) is now available.

On January 12, 2026, Milestone Pharmaceuticals closed a previously arranged royalty financing transaction under a Royalty Purchase Agreement with RTW Royalty I DAC, an affiliate of RTW Investments, whereby funds managed by RTW paid $75 million to acquire a royalty interest in future tiered quarterly royalty payments on U.S. net product sales of etripamil. The closing of this sale, contingent on prior U.S. Food and Drug Administration approval of etripamil, provided Milestone with significant non-dilutive capital in exchange for a portion of future U.S. sales, potentially strengthening its financial position while shifting some long-term revenue upside to RTW.

The most recent analyst rating on (MIST) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.

Spark’s Take on MIST Stock

According to Spark, TipRanks’ AI Analyst, MIST is a Neutral.

The score is held down primarily by weak financial performance (no revenue, large and widening losses, and accelerating cash burn alongside higher leverage). Corporate events are a major offset (FDA approval and EMA MAA acceptance), but technicals remain soft and valuation metrics provide limited support due to ongoing losses.

To see Spark’s full report on MIST stock, click here.

More about Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing etripamil, a fast-acting calcium channel blocker, for the treatment of cardiovascular conditions, with a primary market focus on the United States.

Average Trading Volume: 5,079,241

Technical Sentiment Signal: Buy

Current Market Cap: $173.7M

Find detailed analytics on MIST stock on TipRanks’ Stock Analysis page.